KEGG   DRUG: Elbasvir and grazoprevir
Entry
D10778            Mixture   Drug                                   
Name
Elbasvir and grazoprevir;
Zepatier (TN)
Product
Component
Elbasvir [DR:D10625], (Grazoprevir hydrate [DR:D10639] | Grazoprevir [DR:D11565])
Class
Antiviral
 DG03198  Anti-HCV agent
Remark
ATC code: J05AP54
Product: D10778<US>
Efficacy
Antiviral
  Disease
Chronic hepatitis C [DS:H00413]
Comment
treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection
Target
HCV NS3/4A protease [KO:K22273 K22274]
HCV NS5A [KO:K22275]
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko05160  Hepatitis C
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP54 Elbasvir and grazoprevir
      D10778  Elbasvir and grazoprevir <US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-hepatitis C (HCV) Agents
   Elbasvir/ Grazoprevir
    D10778  Elbasvir and grazoprevir
Drug groups [BR:br08330]
 Antiviral
  DG03198  Anti-HCV agent
   D10778  Elbasvir and grazoprevir
Drug classes [BR:br08332]
 Antiviral
  DG03198  Anti-HCV agent
   D10778  Elbasvir and grazoprevir
Antimicrobials [BR:br08307]
 Antivirals
  Polyprotein cleavage inhibitor
   HCV NS3/4A inhibitor
    D10778  Elbasvir and grazoprevir <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10778
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10778
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10778
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D10778
Other DBs
PubChem: 313046636
ChEBI: 132973

» Japanese version   » Back

DBGET integrated database retrieval system